Elanco Animal Health Incorporated

Equities

ELAN

US28414H1032

Pharmaceuticals

Real-time Estimate Cboe BZX 09:16:09 09/05/2024 pm IST 5-day change 1st Jan Change
17 USD +0.62% Intraday chart for Elanco Animal Health Incorporated +25.61% +13.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BofA Securities Adjusts Price Target on Elanco Animal Health to $20 From $18, Maintains Buy Rating MT
Elanco Animal Health Shares Rise as Q1 Earnings, Revenue Beat Estimates MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Traders Seek Rate Clues MT
Elanco Animal Health Q1 Adjusted Earnings, Revenue Decline; 2024 Earnings Outlook Raised; Shares Rise Pre-Bell MT
Earnings Flash (ELAN) ELANCO ANIMAL HEALTH Reports Q1 Revenue $1.21B, vs. Street Est of $1.17B MT
Earnings Flash (ELAN) ELANCO ANIMAL HEALTH Posts Q1 EPS $0.34, vs. Street Est of $0.27 MT
Transcript : Elanco Animal Health Incorporated, Q1 2024 Earnings Call, May 08, 2024
Elanco Animal Health Incorporated Updates Earnings Guidance for the Full Year 2024 CI
Elanco Animal Health Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Elanco Animal Health Incorporated Updates Earnings Guidance for the Second Quarter 2024 CI
Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board MT
Elanco appoints two directors after settling with activist Ancora RE
Elanco appoints two directors to its board after agreement with Ancora RE
Elanco Animal Health Incorporated Appoints Kathy Turner and Craig Wallace, to Its Board of Directors CI
Elanco Animal Health Enters into Cooperation Agreement with Ancora Advisors CI
Activist investor Ancora secures two Elanco board seats, Bloomberg News reports RE
Transcript : Elanco Animal Health Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 04:05 PM
Elanco Animal Health Insider Bought Shares Worth $322,808, According to a Recent SEC Filing MT
Transcript : Elanco Animal Health Incorporated Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 10:30 AM
Elanco Animal Health Incorporated Appoints Shiv O'Neill as Executive Vice President, General Counsel and Corporate Secretary CI
Elanco Animal Health Incorporated Sends Communication to its Employees CI
Elanco Animal Health Incorporated Issues a Statement in Response to the Submission of Nominees by Ancora Holdings Group CI
Ancora seeks four board seats at Elanco amid push for changes RE
Elanco Animal Health Issues Response to Ancora Holdings' Board Nominations MT
Chart Elanco Animal Health Incorporated
More charts
Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, poultry, and aquaculture. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
16.89 USD
Average target price
18.3 USD
Spread / Average Target
+8.33%
Consensus
  1. Stock Market
  2. Equities
  3. ELAN Stock
  4. News Elanco Animal Health Incorporated
  5. Elanco Animal Health's Q4 Adjusted Earnings Fall, Revenue Rises; 2024 Guidance Issued
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW